RVPH
Reviva Pharmaceuticals Holdings, Inc.
Price Chart
Latest Quote
$0.35
-0.04 (-10.60%)
Current Price
| Previous Close | $0.39 |
| Open | $0.39 |
| Day High | $0.39 |
| Day Low | $0.31 |
| Volume | 40,635 |
Stock Information
| Shares Outstanding | 13.11M |
| Total Debt | $144K |
| Cash Equivalents | $19.89M |
| Net Income | $-13.02M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $4.59M |
| EPS (TTM) | $-1.44 |
| Exchange | OQB |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $-15.16M |
| Income | $-13.02M |
| Book/sh | $1.16 |
| Cash/sh | $1.52 |
| Employees | 14 |
Financial Ratios
| Quick Ratio | 3.35 |
| Current Ratio | 3.56 |
| Debt/Eq | 0.95 |
Returns & Margins
| ROA | -51.40% |
| ROE | -176.60% |
Ownership
| Insider Ownership | 7.73% |
| Institutional Ownership | 8.24% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -0.41 |
| P/B | 0.30 |
Analyst Data
| Recommendation | none |
| Target Price | $17.50 |
Technical Indicators
| SMA20 | $0.46 |
| SMA50 | $0.49 |
| SMA200 | $1.51 |
| RSI | 25.11 |
| ATR | 0.0677 |
| Shares Float | 11.86M |
| Short Float | 14.95% |
| Short Ratio | 3.35 |
| Volatility | 0.48 |
| Rel Volume | 3.28 |
Performance History
| Week | -21.88% |
| Month | -30.00% |
| Quarter | -12.52% |
| 6 Months | -60.22% |
| YTD | -94.35% |
| Year | -97.02% |
| 3 Years | -99.53% |
| 5 Years | -99.50% |
| 10 Years | -99.78% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-10-30 | $0.35 | 110,029 |
| 2026-10-29 | $0.39 | 9,742 |
| 2026-10-28 | $0.41 | 23,255 |
| 2026-10-27 | $0.45 | 11,444 |
| 2026-10-26 | $0.43 | 39,612 |
| 2026-10-23 | $0.45 | 13,017 |
| 2026-10-22 | $0.47 | 28,875 |
| 2026-10-21 | $0.44 | 27,458 |
| 2026-10-20 | $0.46 | 32,423 |
| 2026-10-19 | $0.45 | 33,977 |
| 2026-10-16 | $0.47 | 38,463 |
| 2026-10-15 | $0.47 | 94,660 |
| 2026-10-14 | $0.48 | 23,544 |
| 2026-10-13 | $0.50 | 15,234 |
| 2026-10-12 | $0.49 | 17,554 |
| 2026-10-09 | $0.50 | 11,914 |
| 2026-10-08 | $0.49 | 21,108 |
| 2026-10-07 | $0.50 | 57,246 |
| 2026-10-06 | $0.51 | 19,259 |
| 2026-10-05 | $0.51 | 42,354 |
| 2026-10-02 | $0.50 | 59,250 |
| 2026-10-01 | $0.50 | 9,953 |
| 2026-09-30 | $0.47 | 12,236 |
About Reviva Pharmaceuticals Holdings, Inc.
Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of neuropsychiatric indications, such as schizophrenia, bipolar disorder, major depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis. It also engages in the clinical development for respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis. In addition, the company is in preclinical development for the treatment of psoriasis; and RP1208 for the treatment of depression and obesity. The company was founded in 2018 and is headquartered in Cupertino, California.
đ° Latest News
No news articles available at the moment. Check back later for updates on RVPH.
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Interest Expense | $13,402 | $18,497 | $33,725 | - |
| Total Expenses | $20,200,031 | $30,798,889 | $39,503,636 | $28,228,758 |
| Other Income Expense | $56,050 | $556,729 | $-104,940 | $-194,709 |
| Other Non Operating Income Expenses | $-32,960 | $-160,916 | $134,276 | - |
| Net Non Operating Interest Income Expense | $297,968 | $342,872 | $364,688 | $182,802 |
| Interest Expense Non Operating | $13,402 | $18,497 | $33,725 | - |
| Operating Expense | $20,200,031 | $30,798,889 | $39,503,636 | $28,228,758 |
| General And Administrative Expense | $8,491,125 | $7,891,521 | $8,083,819 | $5,358,734 |
| Total Other Finance Cost | - | - | - | $-182,802 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-19,864,902 | $-29,918,802 | $-39,260,837 | $-28,261,442 |
| Net Interest Income | $297,968 | $342,872 | $364,688 | $182,802 |
| Interest Income | $311,370 | $361,369 | $398,413 | $182,802 |
| Normalized Income | $-19,935,220 | $-30,485,742 | $-39,071,856 | $-28,107,622 |
| Net Income From Continuing And Discontinued Operation | $-19,864,902 | $-29,918,802 | $-39,260,837 | $-28,261,442 |
| Total Operating Income As Reported | $-20,200,031 | $-30,798,889 | $-39,503,636 | $-28,228,758 |
| Net Income Common Stockholders | $-19,864,902 | $-29,918,802 | $-39,260,837 | $-28,261,442 |
| Net Income | $-19,864,902 | $-29,918,802 | $-39,260,837 | $-28,261,442 |
| Net Income Including Noncontrolling Interests | $-19,864,902 | $-29,918,802 | $-39,260,837 | $-28,261,442 |
| Net Income Continuous Operations | $-19,864,902 | $-29,918,802 | $-39,260,837 | $-28,261,442 |
| Pretax Income | $-19,846,013 | $-29,899,288 | $-39,243,888 | $-28,240,665 |
| Interest Income Non Operating | $311,370 | $361,369 | $398,413 | $182,802 |
| Operating Income | $-20,200,031 | $-30,798,889 | $-39,503,636 | $-28,228,758 |
| Per Share | ||||
| Diluted EPS | - | $-18.00 | $-33.00 | $-25.00 |
| Basic EPS | - | $-18.00 | $-33.00 | $-25.00 |
| Other | ||||
| Tax Effect Of Unusual Items | $18,692 | $150,705 | $-50,235 | $-40,889 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-19,921,621 | $-30,598,436 | $-38,970,947 | $-28,034,049 |
| Total Unusual Items | $89,010 | $717,645 | $-239,216 | $-194,709 |
| Total Unusual Items Excluding Goodwill | $89,010 | $717,645 | $-239,216 | $-194,709 |
| EBITDA (Bullshit earnings) | $-19,832,611 | $-29,880,791 | $-39,210,163 | $-28,228,758 |
| EBIT | $-19,832,611 | $-29,880,791 | $-39,210,163 | $-28,228,758 |
| Diluted NI Availto Com Stockholders | $-19,864,902 | $-29,918,802 | $-39,260,837 | $-28,261,442 |
| Tax Provision | $18,889 | $19,514 | $16,949 | $20,777 |
| Gain On Sale Of Security | $89,010 | $717,645 | $-239,216 | $-194,709 |
| Research And Development | $11,708,906 | $22,907,368 | $31,419,817 | $22,870,024 |
| Selling General And Administration | $8,491,125 | $7,891,521 | $8,083,819 | $5,358,734 |
| Other Gand A | $8,491,125 | $7,891,521 | $8,083,819 | $5,358,734 |
| Diluted Average Shares | - | $1,657,371 | $1,189,910 | $975,823 |
| Basic Average Shares | - | $1,657,371 | $1,189,910 | $975,823 |
| Reconciled Depreciation | - | - | - | - |
Fetched: 2026-05-13
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $8,647,645 | $812,572 | $5,718,716 | $8,394,246 |
| Total Assets | $15,923,198 | $15,503,088 | $23,700,388 | $18,923,675 |
| Total Non Current Assets | $819,721 | $819,721 | $0 | $0 |
| Non Current Prepaid Assets | $819,721 | $819,721 | $0 | - |
| Current Assets | $15,103,477 | $14,683,367 | $23,700,388 | $18,923,675 |
| Other Current Assets | $664,685 | $666,435 | $254,637 | $403,819 |
| Prepaid Assets | $0 | $540,601 | $78,295 | $403,819 |
| Cash Cash Equivalents And Short Term Investments | $14,438,792 | $13,476,331 | $23,367,456 | $18,519,856 |
| Cash And Cash Equivalents | $14,438,792 | $13,476,331 | $23,367,456 | $18,519,856 |
| Cash Equivalents | $13,228,720 | $12,203,627 | $22,211,820 | - |
| Cash Financial | $1,210,072 | $1,272,704 | $1,155,636 | - |
| Debt | ||||
| Total Debt | $406,875 | $458,154 | - | - |
| Current Debt And Capital Lease Obligation | $406,875 | $458,154 | - | - |
| Current Debt | $406,875 | $458,154 | - | - |
| Other Current Borrowings | $406,875 | $458,154 | - | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $7,275,553 | $14,690,516 | $17,981,672 | $10,529,429 |
| Total Non Current Liabilities Net Minority Interest | $0 | $89,010 | $806,655 | $567,439 |
| Derivative Product Liabilities | $0 | $89,010 | $806,655 | $567,439 |
| Current Liabilities | $7,275,553 | $14,601,506 | $17,175,017 | $9,961,990 |
| Payables And Accrued Expenses | $6,382,779 | $13,507,765 | $16,216,410 | $9,397,344 |
| Payables | $3,009,074 | $6,283,430 | $3,849,108 | $3,520,271 |
| Accounts Payable | $3,009,074 | $6,283,430 | $3,849,108 | $3,520,271 |
| Equity | ||||
| Common Stock Equity | $8,647,645 | $812,572 | $5,718,716 | $8,394,246 |
| Total Equity Gross Minority Interest | $8,647,645 | $812,572 | $5,718,716 | $8,394,246 |
| Stockholders Equity | $8,647,645 | $812,572 | $5,718,716 | $8,394,246 |
| Retained Earnings | $-184,137,952 | $-164,273,050 | $-134,354,248 | $-95,093,411 |
| Other | ||||
| Ordinary Shares Number | $5,872,865 | $2,328,959 | $1,395,928 | $1,022,368 |
| Share Issued | $5,872,865 | $2,328,959 | $1,395,928 | $1,022,368 |
| Tangible Book Value | $8,647,645 | $812,572 | $5,718,716 | $8,394,246 |
| Invested Capital | $9,054,520 | $1,270,726 | $5,718,716 | $8,394,246 |
| Working Capital | $7,827,924 | $81,861 | $6,525,371 | $8,961,685 |
| Total Capitalization | $8,647,645 | $812,572 | $5,718,716 | $8,394,246 |
| Additional Paid In Capital | $192,773,942 | $165,080,964 | $140,070,172 | $103,485,612 |
| Capital Stock | $11,655 | $4,658 | $2,792 | $2,045 |
| Common Stock | $11,655 | $4,658 | $2,792 | $2,045 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Pensionand Other Post Retirement Benefit Plans Current | $485,899 | $635,587 | $958,607 | $564,646 |
| Current Accrued Expenses | $3,373,705 | $7,224,335 | $12,367,302 | $5,877,073 |
Fetched: 2026-05-13
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-24,594,643 | $-33,543,916 | $-28,324,353 | $-18,960,581 |
| Operating Activities | ||||
| Operating Cash Flow | $-24,594,643 | $-33,543,916 | $-28,324,353 | $-18,960,581 |
| Cash Flow From Continuing Operating Activities | $-24,594,643 | $-33,543,916 | $-28,324,353 | $-18,960,581 |
| Operating Gains Losses | $-89,010 | $-717,645 | $239,216 | $194,709 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $18,632,318 | $23,194,488 | $27,494,103 | $7,773,527 |
| Financing Cash Flow | $25,557,104 | $23,652,791 | $33,171,953 | $7,792,493 |
| Cash Flow From Continuing Financing Activities | $25,557,104 | $23,652,791 | $33,171,953 | $7,792,493 |
| Net Common Stock Issuance | $18,632,318 | $23,194,488 | $27,494,103 | $7,773,527 |
| Common Stock Issuance | $18,632,318 | $23,194,488 | $27,494,103 | $7,773,527 |
| Other | ||||
| Repayment Of Debt | $-458,154 | $-518,750 | $-667,500 | $0 |
| Issuance Of Debt | $406,875 | $976,904 | $667,500 | $0 |
| Interest Paid Supplemental Data | $13,402 | $18,497 | $30,622 | $0 |
| Income Tax Paid Supplemental Data | $3,369 | $3,417 | $19,754 | $16,484 |
| End Cash Position | $14,438,792 | $13,476,331 | $23,367,456 | $18,519,856 |
| Beginning Cash Position | $13,476,331 | $23,367,456 | $18,519,856 | $29,687,944 |
| Changes In Cash | $962,461 | $-9,891,125 | $4,847,600 | $-11,168,088 |
| Proceeds From Stock Option Exercised | $6,976,065 | $149 | $5,677,850 | $18,966 |
| Net Issuance Payments Of Debt | $-51,279 | $458,154 | $0 | $0 |
| Net Short Term Debt Issuance | $-51,279 | $458,154 | $0 | $0 |
| Short Term Debt Payments | $-458,154 | $-518,750 | $-667,500 | $0 |
| Short Term Debt Issuance | $406,875 | $976,904 | $667,500 | $0 |
| Change In Working Capital | $-6,868,590 | $-4,537,810 | $7,283,914 | $8,929,417 |
| Change In Payables And Accrued Expense | $-7,410,941 | $-2,843,985 | $7,213,027 | $7,617,179 |
| Change In Accrued Expense | $-4,003,168 | $-5,135,171 | $6,884,190 | $4,606,491 |
| Change In Payable | $-3,407,773 | $2,291,186 | $328,837 | $3,010,688 |
| Change In Account Payable | $-3,407,773 | $2,291,186 | $328,837 | $3,010,688 |
| Change In Prepaid Assets | $542,351 | $-1,693,825 | $70,887 | $1,312,238 |
| Stock Based Compensation | $2,227,859 | $1,630,341 | $3,413,354 | $176,735 |
| Gain Loss On Investment Securities | $-89,010 | $-717,645 | $239,216 | $194,709 |
| Net Income From Continuing Operations | $-19,864,902 | $-29,918,802 | $-39,260,837 | $-28,261,442 |
| Net Long Term Debt Issuance | - | - | - | - |
| Long Term Debt Issuance | - | - | - | - |
| Change In Interest Payable | - | - | - | - |
| Other Non Cash Items | - | - | - | - |
| Depreciation Amortization Depletion | - | - | - | - |
| Depreciation And Amortization | - | - | - | - |
| Depreciation | - | - | - | - |
Fetched: 2026-05-13